medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2023, Number 1

<< Back

Rev Nefrol Dial Traspl 2023; 43 (1)

New therapeutic strategies to treat hyperphosphatemia in CRF: focus on intestinal absorption

Negri AL

Language: Spanish
References: 19
Page: 57-62
PDF size: 108.07 Kb.


ABSTRACT

Management of hyperphosphatemia in patients with chronic renal failure on dialysis remains challenging. Despite using a multifaceted approach that includes dietary restriction, phosphorus removal by dialysis, and phosphate binders, these multiple strategies fail to reduce phosphorus levels by more than 2 mg/dL. Phosphorus control in dialysis patients is essential due to the monotonic relationship between serum phosphate levels and increased cardiovascular risk. trerefore, there is a need to explore new strategies to reduce serum phosphate levels to normal levels. Recent advances in understanding the mechanisms underlying phosphorus homeostasis suggest that the gastrointestinal transport of phosphorus could be a target. Inhibitors of intestinal sodium phosphate cotransporters recently developed, and using of nicotinamide, in its prolonged release formulation, which would also act by this mechanism, has been revalued. there have also been drugs such as tenapanor, which, by inhibiting the isoform three sodium/hydrogen exchanger of the enterocyte, decreases the paracellular absorption of phosphorus.


REFERENCES

  1. Tonelli M, Pannu N, Manns B Oral phosphate bindersin patients with Kidney failure. N Engl J Med 2010; 362(14): 1312-24

  2. Fouque D, Vervlot M, Ketteler M Targetinggastrointestinal transport proteins to controlhyperphosphatemia in chronic kidney disease. Drugs2018; 78:1171-1186.

  3. Yee J, Rosembaum D, Jacobs J, Sprague SM. Smallintestinal Phosphate absorption: Novel therapeuticimplications. Am J Neprol 2021; 52:522-530.

  4. Forster IC, Hernanado N, Biber J, Murer H. Phosphatetransporters of the SLC20 and SLC34 families. Mol Aspects Med. 2013; 34 (2-3):386-95.

  5. Taniguchi K, Terai K, Terada Y, Tomura Y Novel NaPi-IIb inhibitor ASP3325 inhibits phosphate absorptionin intestine and reduces plasma phosphorus level inrats with renal failure ¨FR-PO936 J Am Soc Nephrol2015; 26:382 A.

  6. Larson TE, Kameoka C, Nakayo I, Taniuchi Y,Yoshida S,Akizawa T et al. NPT-IIb inhibition doesnot improve hyperphosphatemia in CKD. Kidney IntRep. 2018; 3:73-80

  7. EOS789, a novel pan-phosphate transporter inhibitor,is eective for the treatment of chronic kidney disease-mineral bone disorder. Kidney International 2020; 98:343-354.

  8. Hill Gallant KM, Tremke ER, Trevino LL et alEOS789, a broad-spectrum inhibitor of phosphatetransport, is safe with an indication of ecacy in aphase 1b randomized crossover trial in hemodialysispatients. Kidney Int 2021; 99(5):1225-1233.

  9. Tatsumi S, Katai K, Kaneko I, Segawa H, MiyamotoKI. NAD metabolism and the SLC34 family: evidencefor a liver-kidney axis regulating inorganic phosphate.P thugers Archiv 2019;471(1):109-122

  10. Eto N, Miyata Y, Ohno H, Yamashita Nicotinamideprevents the development of hyperphosphatemia bysuppressing intestinal sodium-dependent phosphatetransport in rats with adenine -induced renal failure.Nephrol Dial Transplant 2005; 20(7):1378-84

  11. Takahashi Y, Tanaka A, Nakamura T, Fukuwatari T,Shibata K, Shimada N et al. Nicotinamide suppresseshyperfosfatemia in hemodialysis patients. Kidney Int2004; 65(3):1099-104

  12. Cheng SC, Young DO, Husang Y, Delmez JA, CoyneDW A randomized double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus inhemodialysis patients; Clin J Am Soc Nephrol. 2008;3(4):1131–1138

  13. Ix JH, Isakova T, Larive B, Raphael KL, Raj DS,Cheung AK, Sprague SM, Fried LF, Gassman JJ,Middleton JP, Flessner MF, Block GA, Wolf M.Eects of Nicotinamide and Lanthanum Carbonateon Serum Phosphate and Fibroblast Growth Factor-23in CKD: the COMBINE Trial. J Am Soc Nephrol.2019;30(6):1096-1108.

  14. Ketteler M, Wiecek A, Rosenkranz AR, Ose C,Rekowski J, Lorenz H, Hellmann B, Karus M,Ruhmann M, Ammer R. Ecacy and Safety of aNovel Nicotinamide Modithed-Release Formulationin the Treatment of Refractory Hyperphosphatemiain Patients Receiving Hemodialysis-A RandomizedClinical Trial. Kidney Int Rep. 2020 19;6(3):594-604.

  15. Zhang Y, Ma T, Zhang P. Ecacy and safetyof nicotinamide on phosphorus metabolism inhemodialysis patients. A systematic review and meta-analysis Medicine 2018; 97:41(e12731)

  16. Labonte ED, Carreras CW, Leadbetter MR, KozukaK, Kohler J, Koo-McCoy S, He L, Dy E, Black D,Zhong Z, Langsetmo I, Spencer AG, Bell N, DeshpandeD, Navre M, Lewis JG, Jacobs JW, Charmot D.Gastrointestinal Inhibition of Sodium-HydrogenExchanger 3 Reduces Phosphorus Absorption andProtects against Vascular Calcification in CKD. J AmSoc Nephrol 2015;26(5):1138-49

  17. Block GA, Rosenbaum DP, Yan A, ChertowGM. Ecacy and safety of tenapanor in patientswith hyperphosphatemia receiving maintenancehemodialysis: a randomized phase 3 trial. J Am SocNephrol. 2019;30(4):641–652.

  18. Block GA, Bleyer AJ, Silva AL et al Safety and ecacyof tenapanor for long-term serum phosphate control inmaintenance dialysis: a 52-week randomized Phase 3trial (PHREEDOM). Kidney 360 2021; 2(10):1600-1610.

  19. Pergola PE, Rosenbaum DP, Yang Y, Chertow GM. Arandomized trial of tenapanor and phosphate bindersas a dual-mechanism treatment for hyperphosphatemiain patients on maintenance dialysis (AMPLIFY). J AmSoc Nephrol. 2021;32(6):1465–1473.




2020     |     www.medigraphic.com